Cargando…

Algorithm of Femoropopliteal Endovascular Treatment

Background and Objectives: Indications for the endovascular treatment of femoropopliteal lesions have steadily increased over the past decade. Accordingly, the number of devices has also increased, but the choice of the best endovascular treatment remains to be defined. Many devices are now availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubosq, Maxime, Raux, Maxime, Nasr, Bahaa, Gouëffic, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501396/
https://www.ncbi.nlm.nih.gov/pubmed/36143968
http://dx.doi.org/10.3390/medicina58091293
_version_ 1784795464303902720
author Dubosq, Maxime
Raux, Maxime
Nasr, Bahaa
Gouëffic, Yann
author_facet Dubosq, Maxime
Raux, Maxime
Nasr, Bahaa
Gouëffic, Yann
author_sort Dubosq, Maxime
collection PubMed
description Background and Objectives: Indications for the endovascular treatment of femoropopliteal lesions have steadily increased over the past decade. Accordingly, the number of devices has also increased, but the choice of the best endovascular treatment remains to be defined. Many devices are now available for physicians. However, in order to obtain a high success rate, it is necessary to respect an algorithm whose choice of device is only one step in the treatment. Materials and Methods: The first step is, therefore, to define the approach according to the lesion to be treated. Anterograde approaches (femoral, radial, or humeral) are distinguished from retrograde approaches depending on the patient’s anatomy and surgical history. Secondarily, the lesion will be crossed intraluminally or subintimally using a catheter or an angioplasty balloon. The third step corresponds to the preparation of the artery, which is essential before the implantation of the device. It has a crucial role in reducing the rate of restenosis. Several tools are available and are chosen according to the lesion requiring treatment (stenosis, occlusion). Among them, we find the angioplasty balloon, the atherectomy probes, or intravascular lithotripsy. Finally, the last step corresponds to the choice of the device to be implanted. This is also based on the nature of the lesion, which is considered short, up to 15 cm and complex beyond that. The choice of device will be between bare stents, covered stents, drug-coated balloons, and drug-eluting stents. Currently, drug-eluting stents appear to be the treatment of choice for short lesions, and active devices seem to be the preferred treatment for more complex lesions, although there is a lack of data. Results: In case of failure to cross the lesion, the retrograde approach is a safe and effective alternative. Balloon angioplasty currently remains the reference method for the preparation of the artery, the aim of which is to ensure the intraoperative technical success of the treatment (residual stenosis < 30%), to limit the risk of dissection and, finally, to limit the occurrence of restenosis. Concerning the treatment, the drug-eluting devices seem to present the best results, whether for simple or complex lesions. Conclusions: Endovascular treatment for femoropopliteal lesions needs to be considered upstream of the intervention in order to anticipate the treatment and the choice of devices for each stage.
format Online
Article
Text
id pubmed-9501396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95013962022-09-24 Algorithm of Femoropopliteal Endovascular Treatment Dubosq, Maxime Raux, Maxime Nasr, Bahaa Gouëffic, Yann Medicina (Kaunas) Article Background and Objectives: Indications for the endovascular treatment of femoropopliteal lesions have steadily increased over the past decade. Accordingly, the number of devices has also increased, but the choice of the best endovascular treatment remains to be defined. Many devices are now available for physicians. However, in order to obtain a high success rate, it is necessary to respect an algorithm whose choice of device is only one step in the treatment. Materials and Methods: The first step is, therefore, to define the approach according to the lesion to be treated. Anterograde approaches (femoral, radial, or humeral) are distinguished from retrograde approaches depending on the patient’s anatomy and surgical history. Secondarily, the lesion will be crossed intraluminally or subintimally using a catheter or an angioplasty balloon. The third step corresponds to the preparation of the artery, which is essential before the implantation of the device. It has a crucial role in reducing the rate of restenosis. Several tools are available and are chosen according to the lesion requiring treatment (stenosis, occlusion). Among them, we find the angioplasty balloon, the atherectomy probes, or intravascular lithotripsy. Finally, the last step corresponds to the choice of the device to be implanted. This is also based on the nature of the lesion, which is considered short, up to 15 cm and complex beyond that. The choice of device will be between bare stents, covered stents, drug-coated balloons, and drug-eluting stents. Currently, drug-eluting stents appear to be the treatment of choice for short lesions, and active devices seem to be the preferred treatment for more complex lesions, although there is a lack of data. Results: In case of failure to cross the lesion, the retrograde approach is a safe and effective alternative. Balloon angioplasty currently remains the reference method for the preparation of the artery, the aim of which is to ensure the intraoperative technical success of the treatment (residual stenosis < 30%), to limit the risk of dissection and, finally, to limit the occurrence of restenosis. Concerning the treatment, the drug-eluting devices seem to present the best results, whether for simple or complex lesions. Conclusions: Endovascular treatment for femoropopliteal lesions needs to be considered upstream of the intervention in order to anticipate the treatment and the choice of devices for each stage. MDPI 2022-09-16 /pmc/articles/PMC9501396/ /pubmed/36143968 http://dx.doi.org/10.3390/medicina58091293 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dubosq, Maxime
Raux, Maxime
Nasr, Bahaa
Gouëffic, Yann
Algorithm of Femoropopliteal Endovascular Treatment
title Algorithm of Femoropopliteal Endovascular Treatment
title_full Algorithm of Femoropopliteal Endovascular Treatment
title_fullStr Algorithm of Femoropopliteal Endovascular Treatment
title_full_unstemmed Algorithm of Femoropopliteal Endovascular Treatment
title_short Algorithm of Femoropopliteal Endovascular Treatment
title_sort algorithm of femoropopliteal endovascular treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501396/
https://www.ncbi.nlm.nih.gov/pubmed/36143968
http://dx.doi.org/10.3390/medicina58091293
work_keys_str_mv AT dubosqmaxime algorithmoffemoropoplitealendovasculartreatment
AT rauxmaxime algorithmoffemoropoplitealendovasculartreatment
AT nasrbahaa algorithmoffemoropoplitealendovasculartreatment
AT gouefficyann algorithmoffemoropoplitealendovasculartreatment